

NRG Oncology Presentation Schedule

Advancing Research. Improving Lives.™

Oral and Poster Presentations

JUNE 2-6, 2023

| Disease Site & Study # | Saturday, June 3, 2023 | Time/Location |
|---|---|--|
| Genitourinary-Prostate NRG/TOG 0521 | Title: <i>Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.</i> Presenter: Ryan Phillips, MD Abstract #: 5094 Poster Bd #: 188 | Location: Hall A On Demand Session: Genitourinary Cancer-Prostate, Testicular, and Penile Time: 8:00 AM-11:00 AM CDT Poster Session |
| Genitourinary-Bladder NRG/TOG 0524 NRG/TOG 0712 | Title: <i>Prognostic significance of pretreatment immune cell infiltration in muscle invasive bladder cancer treated with definitive chemoradiation: Analysis of NRG RTOG 0524 and 0712.</i> Presenter: Matthew P Deek, MD Abstract #: 4523 Poster Bd #: 15 | Location: Hall A On Demand Session: Genitourinary Cancer-Kidney and Bladder Time: 8:00 AM-11:00 AM CDT Poster Session |
| Genitourinary-Bladder NRG-GU012 | Title: <i>NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).</i> Presenter: Rana R McKay, MD (William Hall) Abstract: TPS4604 Poster Bd #: 94b | Location: Hall A On Demand Session: Genitourinary Cancer-Kidney and Bladder Time: 8:00 AM-11:00 AM CDT Poster Session |
| Gynecologic Cancer NRG-GY006 | Title: <i>Incorporation of triopine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.</i> Presenter: Charles Leath, MD Abstract #: 5502 | Location: Hall D1 Live Stream Session: Gynecologic Cancer Presentation – Gynecologic Cancer Time: 3:24 PM – 3:36 PM CDT Oral Abstract Session |
| Disease Site & Study # | Sunday, June 4, 2023 | Time/Location |
| Genitourinary-Prostate NRG/TOG-9202 | Title: <i>Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials.</i> Presenter: Andrew J Armstrong, MD Abstract #: 5001 | Location: Hall B1 Live Stream Session: Genitourinary Cancer Prostate, Testicular, and Penile Time: 8:12 AM-8:24 AM CDT Oral Abstract Session |
| Breast NRG-BR007 | Title: <i>NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.</i> Presenter: Julia White, MD Abstract #: TPS 623 Poster Bd #: 449a | Location: Hall A On Demand Session: Breast Cancer-Local/Regional/Adjuvant Time: 8:00 AM-11:00 AM CDT Poster Session |

| Disease Site & Study # | Monday, June 5, 2023 | Time/Location |
|--------------------------------|--|--|
| Gastrointestinal NRG-GI008 | Title: <i>Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).</i> Presenter: Van K Morris, MD Abstract #: TPS3625 Poster Bd #: 324b | Location: Hall A On Demand Session: Gastrointestinal Cancer-Colorectal and Anal Time: 8:00 AM-11:00 AM CDT Poster Session |
| Gastrointestinal NRG-GI008 | Title: <i>Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.</i> Presenter: Arvind Dasari, MD Abstract #: TPS3634 Poster Bd #: 329a | Location: Hall A On Demand Session: Gastrointestinal Cancer-Colorectal and Anal Time: 8:00 AM-11:00 AM CDT Poster Session |
| Head and Neck NRG/RT0G 9512 | Title: <i>Association between locoregional failure and NFE2L2/KEAP1/CUL3 pathway mutations in NRG/RT0G 9512: A randomized trial of hyperfractionation vs. conventional fractionation in T2N0 glottic squamous cell carcinoma (SCC).</i> Presenter: David N Hayes, MD, MPH (Li Guan) Abstract #: 6054 Poster Bd #: 449a | Location: Hall A On Demand Session: Head and Neck Cancer Time: 1:15 PM-4:15 PM CDT Poster Session |
| Gynecologic NRG/RT0G 1203 | Title: <i>Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RT0G 1203.</i> Presenter: Kelsey Corrigan, MD Abstract #: 5533 Poster Bd #: 228 | Location: Hall A On Demand Session: Gynecologic Cancer Time: 1:15 PM-4:15 PM CDT Poster Session |
| Gynecologic NRG-GY012 | Title: <i>Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG-GY012.</i> Presenter: Helen Mackay Abstract #: 5525 Poster Bd #: 220 | Location: Hall A On Demand Session: Gynecologic Cancer Time: 1:15 PM-4:15 PM CDT Poster Session |
| Gynecologic NRG-GY012 | Title: <i>A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.</i> Presenter: Bobbie J Rimel, MD Abstract #: TPS5629 Poster Bd #: 315b | Location: Hall A On Demand Session: Gynecologic Cancer Time: 1:15 PM-4:15 PM CDT Poster Session |
| Genitourinary NRG/RT0G 0534 | Title: <i>Neurocognitive function outcomes in NRG/RT0G 0534, the SPPORT trial.</i> Presenter: Jeffrey S Wefel, PhD Abstract #: 12022 Poster Bd #: 390 | Location: S404 On Demand Session: Symptoms and Survivorship Time: 4:30 PM-6:00 PM CDT Poster Discussion Session |

| Disease Site & Study # | The following presentations include NRG author/investigators from NCTN sponsored federal trials, and NSABP-RTOG-GOG Foundation studies | Time/Location |
|--|---|---|
| Breast NRG/NSABP B-31 | <p>Title: <i>Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.</i></p> <p>Presenter: Robert K Hills, DPhil</p> <p>Abstract #: 508</p> <p>NRG Author: Sandra Swain, MD</p> | <p>Location: Hall D1 Live Stream</p> <p>Session: Breast Cancer-Local/Regional/Adjuvant</p> <p>Date: 6/2/2023</p> <p>Time: 5:09 PM-5:21 PM CDT</p> <p>Duration: TBD</p> <p>Oral Abstract Session</p> |
| Sarcoma Alliance A92104 | <p>Title: <i>ETCTN/NCI 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for the treatment of unresectable and metastatic conventional chondrosarcoma.</i></p> <p>Presenter: Kristine P Lacuna, MD</p> <p>Abstract #: 11531 Poster Bd #: 465</p> <p>NRG Author: Martee Hensley MD</p> | <p>Location: Hall A On Demand</p> <p>Session: Sarcoma</p> <p>Date: 6/3/2023</p> <p>Time: 1:15 PM-4:15 PM CDT</p> <p>Poster Session</p> |
| Melanoma/Skin Cancers SWOG S2000 | <p>Title: <i>A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.</i></p> <p>Presenter: Zeynep Eroglu, MD</p> <p>Abstract #: TPS9603 Poster Bd #: 360b</p> <p>NRG Author: Rupesh Kotecha, MD</p> | <p>Location: Hall A On Demand</p> <p>Session: Melanoma/Skin Cancers</p> <p>Date: 6/3/2023</p> <p>Time: 1:15 PM-4:15 PM CDT</p> <p>Poster Session</p> |
| Breast NRG/NSABP B-40 NSABP B-41 | <p>Title: <i>Axillary surgery efficacy for patients with breast cancer receiving neoadjuvant chemotherapy on NSABP B40 and B41.</i></p> <p>Presenter: Raymond Mailhot Vega, MD</p> <p>Abstract #: 524 Poster Bd #: 354</p> <p>NRG Author: Eleftherios Mamounas, MD</p> | <p>Location: Hall B1 Live Stream</p> <p>Session: Breast Cancer-Local/Regional/Adjuvant</p> <p>Date: 6/4/2023</p> <p>Time: 4:30 PM-6:00 PM CDT</p> <p>Poster Session</p> |
| Lung Lung-MAP | <p>Title: <i>The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.</i></p> <p>Presenter: Philip C Mack, PhD</p> <p>Abstract #: 9035 Poster Bd #: 23</p> <p>NRG Author: Saiana Waqar, MD</p> | <p>Location: Hall A On Demand</p> <p>Session: Lung Cancer</p> <p>Date: 6/4/2023</p> <p>Time: 8:00 AM-11:00 AM CDT</p> <p>Poster Session</p> |
| Lung Alliance A082101 | <p>Title: <i>Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).</i></p> <p>Presenter: Aaron S Mansfield, MD</p> <p>Abstract #: TPS8602 Poster Bd #: 227b</p> <p>NRG Author: Paul Romesser, MD</p> | <p>Location: Hall A On Demand</p> <p>Session: Lung Cancer</p> <p>Date: 6/4/2023</p> <p>Time: 8:00 AM-11:00 AM CDT</p> <p>Poster Session</p> |
| Lung ECOG-ACRIN LUNG-MAP S1900E | <p>Title: <i>ECOG-ACRIN LUNG-MAP S1900E substudy: A phase II study of sotorasib in participants (Pts) with previously treated stage IV or recurrent KRAS G12C mutant non-squamous (Non-sq) non-small cell lung cancer (NSCLC).</i></p> <p>Presenter: Sukhmani K Padda, MD</p> <p>Abstract #: TPS9143 Poster Bd #: 129a</p> | <p>Location: Hall A On Demand</p> <p>Session: Lung Cancer</p> <p>Date: 6/4/2023</p> <p>Time: 8:00 AM-11:00 AM CDT</p> <p>Poster Session</p> |

| Disease Site & Study # | The following presentations include NRG author/investigators from NCTN sponsored federal trials, and NSABP-ROG-GOG Foundation studies | Time/Location |
|--------------------------------------|---|--|
| Lung A092001 | <p>Title: <i>Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).</i></p> <p>Presenter: Aaron Scott Mansfield, MD</p> <p>Abstract #: TPS8603</p> <p>NRG Author: Thomas George, MD</p> | <p>Location: Hall A On Demand</p> <p>Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers</p> <p>Date: 6/4/2023</p> <p>Time: 8:00 AM-11:00 AM CDT</p> <p>Poster Session</p> |
| Breast LidERA (NSABP B-61) | <p>Title: <i>lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician's choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2- eBC).</i></p> <p>Presenter: Charles Geyer, MD</p> <p>Abstract #: TSP616 Poster Bd #: 445b</p> <p>NRG Author: Charles Geyer, MD</p> | <p>Location: Hall A On Demand</p> <p>Session: Breast Cancer—Local/Regional/Adjuvant</p> <p>Date: 6/4/2023</p> <p>Time: 8:00 AM-11:00 AM CDT</p> <p>Poster Session</p> |
| Breast A011401 | <p>Title: <i>Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.</i></p> <p>Presenter: Jennifer Ligibel, MD</p> <p>Abstract #: 12001</p> <p>NRG Author: Julia White, MD</p> | <p>Location: S100a Live Stream</p> <p>Session: Symptoms and Survivorship</p> <p>Date: 6/5/2023</p> <p>Time: 8:12 AM-8:24 AM CDT</p> <p>Oral Abstract Session</p> |
| Gastrointestinal Alliance A021804 | <p>Title: <i>Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.</i></p> <p>Presenter: Jaydira Del Rivero</p> <p>Abstract #: TSP4191 Poster Bd #: 502a</p> <p>NRG Author: Helosia Soares, MD</p> | <p>Location: Hall A On Demand</p> <p>Session: Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary</p> <p>Date: 6/5/2023</p> <p>Time: 8:00 AM-11:00 AM CDT</p> <p>Poster Session</p> |
| Gastrointestinal Alliance A021806 | <p>Title: <i>A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.</i></p> <p>Presenter: A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.</p> <p>Presenter: Akhil Chawla, MD</p> <p>Abstract #: TPS4204 Poster Bd #: 508b</p> <p>NRG Author: Anna Varghese, MD</p> | <p>Location: Hall A On Demand</p> <p>Session: Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary</p> <p>Date: 6/5/2023</p> <p>Time: 8:00 AM-11:00 AM CDT</p> <p>Poster Session</p> |
| Gastrointestinal SWOG S1609 | <p>Title: <i>A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48).</i></p> <p>Presenter: Sandip Patel, MD</p> <p>Abstract #: e16330 Publication Only</p> <p>NRG Authors: Grace Tarabay, MD; Thomas George, MD</p> | |

| Disease Site & Study # | The following presentations include NRG author/investigators from NCTN sponsored federal trials, and NSABP-ROG-GOG Foundation studies | Time/Location |
|--|---|--|
| Gastrointestinal SWOG S2001 | <p>Title: <i>Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.</i></p> <p>Presenter: Vincent Chung, MD</p> <p>Abstract #: TPS419 Poster Bd #: 505b</p> <p>NRG Author: <u>Carmen Allegra, MD</u></p> | <p>Location: Hall A On Demand</p> <p>Session: Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary</p> <p>Date: 6/5/2023</p> <p>Time: 8:00 AM-11:00 AM CDT</p> <p>Poster Session</p> |
| Gastrointestinal Alliance A022101 | <p>Title: <i>Alliance A022101: A pragmatic, randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: Evaluating Radiation, Ablation, and Surgery (ERASur).</i></p> <p>Presenter: Kathryn Hitchcock, MD, PhD</p> <p>Abstract #: TPS3629 Poster Bd #: 326b</p> <p>NRG Authors: <u>Thomas George, MD; Theodore Hong, MD</u></p> | <p>Location: Hall A On Demand</p> <p>Session: Gastrointestinal Cancer—Colorectal and Anal</p> <p>Date: 6/5/2023</p> <p>Time: 8:00 AM-11:00 AM CDT</p> <p>Poster Session</p> |
| Gastrointestinal Alliance A022102 | <p>Title: <i>Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).</i></p> <p>Presenter: Haeseong Park, MD</p> <p>Abstract #: TPS4175 Poster Bd #: 494a</p> <p>NRG Author: <u>Matthew Strickland, MD</u></p> | <p>Location: Hall A On Demand</p> <p>Session: Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary</p> <p>Date: 6/5/2023</p> <p>Time: 8:00 AM-11:00 AM CDT</p> <p>Poster Session</p> |
| Gastrointestinal Alliance A022104 | <p>Title: <i>Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.</i></p> <p>Presenter: Jesse Joshua Smith, MD, PhD</p> <p>Abstract #: TPS3640 Poster Bd #: 332a</p> <p>NRG Authors: <u>Thomas George, MD; Theodore Hong, MD</u></p> | <p>Location: Hall A On Demand</p> <p>Session: Gastrointestinal Cancer—Colorectal and Anal</p> <p>Date: 6/5/2023</p> <p>Time: 8:00 AM-11:00 AM CDT</p> <p>Poster Session</p> |
| Sarcoma Alliance A091902 | <p>Title: <i>A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).</i></p> <p>Presenter: Juneko E Grilley-Olson, MD</p> <p>Abstract #: 11503</p> <p>NRG Author: <u>Meng X Welliver, MD</u></p> | <p>Location: S100a Live Stream</p> <p>Session: Sarcoma</p> <p>Date: 6/5/2023</p> <p>Time: 12:30-12:42 PM CDT</p> <p>Oral Abstract Session</p> |